HIGH NEWS

CNew York City Opens Third Legal Cannabis Store

DEA Data Shows Marijuana Legalization Linked To ‘Reductions In Opioid Demand,’ New Study Finds

The farmers of Andretti Cannabis Co. have cultivated cannabis for many years and can trace the genetics of their OG back through several generations of cannabis cultivation. This original variety sprang from seed, never crossed, and through years of raids, relocations, and other hardships. At a High Times cup, Curren$y came across this master strain and immediately recognized its unique qualities. He and the producers made the decision to develop Andretti Cannabis after a few meetings, and after months of planning, they debuted at the beginning of 2017 to shock the cannabis industry.

In the largest city in the United States, cannabis retail stores are sprouting up while unlicensed locations continue to prosper despite multiple attempts to close them down. The third adult-use cannabis shop in New York City opened its doors on February 13 in Lower Manhattan.

urren$y Talented Hip Hop MC and successful entrepreneur from New Orleans, Louisiana has surely cemented his name in Hip Hop. His lay back charismatic swag that comes through effortlessly authentic in his raps and his entrepreneurial mentality are keys to his success. Spitta’s journey to become that he is today started in 2002 as a member of No Limit Records. Spitta evolved into a brilliant lyricist with his own style and delivery over the course of a few years of intense mixtape-circuit. Curren$y has achieved a certain kind of mixtape-level cult celebrity in part because he has mastered his easygoing everyday stoner identity and he drops music almost daily making his music easily accessible. Curren$y has built an intimate relationship with his fan base, knowing where his music and products are well received booking events and shows based on that definedly a formula for success.

Union Square Travel Agency: A Cannabis Store will be the newest authorized retailer to operate, and it will be situated on East 13th Street between Broadway and University Place. According to the store’s website, it will sell smokable flower, edibles, concentrates, and vapes. Governor Hochul stated in a statement, “We’re building a cannabis industry here in New York State that is equitable and delivers new resources to Nonprofits that bring supportive services to our communities”. “This is the latest recent milestone in our efforts to grow the cannabis industry while creating jobs and opportunities for those who have historically been disproportionately targeted for cannabis offenses,” the statement reads.

Curren$y being the cannabis connoisseur that he is, helped develop a series of potent strains. The Andretti OG is one of our most sought after strains. Andretti OG is quickly turning heads around the cannabis industry for many reasons. Its high potency, and heavy couch lock high. You may hear people claim that this strain or that strain is linked to Curren$y (also known as Spitta Andretti), but none of the imitators can match the genuine “Andretti OG” strain. After spending months honing its genetics, Andretti OG is the first of a new series of superior cannabis flowers for smokers that want the finest, with a classic OG dankness and stoney high that leaves you speechless.

After the non-profit Housing Works launched one on East 8th Street, Broadway, and Smacked LLC, a store that opened on Bleecker Street last month, it is the third legal cannabis establishment. During the governor’s announcement, the new store management marked the occasion of its opening. “We are incredibly grateful to everyone who has contrib-

According to a recent study that uses data from the federal Drug Enforcement Administration, the legalization of marijuana at the state level is linked to considerable drops in the opioid codeine’s prescription (DEA).

The study, which was released last week in the journal Health Economics, compared 11 states that legalized cannabis for adult use between 2010 and 2019 against prohibitionist ones by examining data on prescription opioid shipments. A “26 percent decrease in retail pharmacy-based codeine distribution” was discovered to be a result of recreational marijuana legalization. The same trend, according to the researchers from Cornell University, George Mason University, the University of Georgia, and the University of Pittsburgh, was not seen for shipments of other opioids, such as hydrocodone and morphine, or to hospitals, which frequently have stricter prescription guidelines. But because codeine is a lower-potency opioid with a significant potential for abuse, the study’s findings “are suggestive that [recreational legalization] may help achieve reductions in opioid overuse.”

Curren$y’s Strain Andretti OG, typically called to as “Andretti” or “Andretti OG Kush,” is an indica-dominant hybrid strain that was developed by crossing the traditional Dosi #9 with an unidentified hybrid strain. This was the first strain launched by The Andretti Cannabis Co. and it was an instant hit loved by not just his dedicated fans but also Cannabis enthusiasts. Before being developed into the strain we have now, Curren$y discovered an old, isolated OG strain during a High Times Cup he attended and experienced its high potency and astronomical effects. The demanding standards that went into creating Andretti OG also went into creating the rest of the strains. Partnering with Cookies was the perfect marketing move for Spitta, a match made in heaven that also contributed to the success of the brand.

Collectively, the study’s findings “are consistent with the notion that, unlike [medical cannabis laws], [recreational cannabis laws] may be evidence of decreased opioid misuse more so than decreased usage of prescription opioids to relieve chronic pain,” the authors said. This research piece is distinctive in that the DEA’s Automation of Reports and Consolidation Orders System served as its “main data source” (ARCOS).

To our knowledge, this is the first study to use ARCOS data, which breaks down distribution by endpoint (pharmacies, hospitals, doctors, and narcotic treatment programs), to analyze the impact of legalizing marijuana for recreational use. The effect of legalization on the prescription of codeine, they said, “rising from -17.5 percent one year after RCL implementation to -37.3 percent four years after implementation,” over time.

“That our findings suggest RCLs affect a reduction specifically in codeine distribution is of particular interest because, among legally distributed opioids, codeine is particularly likely to be misused and diverted,” they ccording to a NORML survey, researchers published more than 4,300 papers on marijuana and its constituent parts in 2022, setting a new yearly record.

We cannot rule out that these reductions are due to a reduction in use of codeine as prescribed; however, the lack of other reductions in opioid dispensing suggests that this is not the case. Our findings stand in contrast to the literature on MCLs, which finds that MCLs affect reductions in the dispensing of a variety of opioids that do not have misuse rates as high as codeine.” According to a recent survey by the Amer ican Medical Association (AMA), one in three people with chronic pain report using marijuana as a thera py option. The majority of this population has substituted cannabis for other painkillers, such as opiates.

A different recent AMA study discovered that legalizing medical marijuana at the state level is linked to a con siderable decline in opioid prescriptions and use among some cancer patients.

One of the most frequent arguments used by opponents of change is that more research is needed, despite the fact that cannabis is one of the most regularly studied medical topics. Most people feel that research on a plant that is the most commonly used illicit substance in the world should continue, particularly as more jurisdictions consider legalizing it in some form. However, there is a widespread cultural assumption that it has not been sufficiently investigated and that there are too many unanswered questions to proceed with policy reform. But according to an analysis of the federal PubMed.gov site conducted by NORML, there were more than 4,300 research articles published worldwide focusing on cannabis this year. That exceeds last year’s total of just over 4,200

“Despite claims by some that marijuana has yet to be subject to adequate scientific scrutiny, scientists’ interest in studying cannabis has increased exponentially in recent years, as has our understanding of the plant, its active constituents, their mechanisms of action, and their effects on both the user and upon society,” NORML Deputy Director Paul Armentano said in a blog post. “It is time for politicians and others to stop assessing cannabis through the lens of ‘what we don’t know’ and instead start engaging in evidence-based discussions about marijuana and marijuana reform policies that are indicative of all that we do know,” he said. Lawmakers and legalization advocates have actually aligned with prohibitionists to support expanded research into cannabis—a point that’s underscored by the fact that President Joe Biden signed a historic standalone bill this month to streamline studies, for

Both the House and Senate passed earlier versions of their separate but similar cannabis research bills in late 2020, but nothing ended up getting to then-President Donald Trump’s desk by the end of the last Congress. Congressional researchers separately released a report in March that details the challenges posed by ongoing federal prohibition and the options that lawmakers have

DEA has taken steps in recent years to approve new cultivators of marijuana to be used in studies, and the National Institute on Drug Abuse (NIDA) recently published a solicitation for applications from those authorized growers as it looks for new contractors

Meanwhile, large-scale infrastructure legislation that was signed by Biden last year contains provisions aimed at allowing researchers to study the actual marijuana that consumers are purchasing from state-legal businesses instead of having to use only government-grown cannabis. Sen. John Hickenlooper (D-CO) recently sought an update on the status of a federal report into research barriers that are inhibiting the development of a standardized test for marijuana impairment on the roads, as required